NASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $14.64 +0.19 (+1.28%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunovant Stock (NASDAQ:IMVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunovant alerts:Sign Up Key Stats Today's Range$14.41▼$14.8950-Day Range$13.31▼$21.2652-Week Range$12.72▼$34.47Volume123,335 shsAverage Volume1.20 million shsMarket Capitalization$2.49 billionP/E RatioN/ADividend YieldN/APrice Target$38.33Consensus RatingModerate Buy Company OverviewImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More… Immunovant Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreIMVT MarketRank™: Immunovant scored higher than 39% of companies evaluated by MarketBeat, and ranked 510th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingImmunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.69) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.85% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 24.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.85% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 24.62%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.57 News SentimentImmunovant has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Immunovant this week, compared to 6 articles on an average week.Search InterestOnly 13 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $690,207.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesImmunovant, Inc. (NASDAQ:IMVT) CFO Sells $44,565.77 in StockApril 18, 2025 | insidertrades.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 28,094 Shares of StockApril 12, 2025 | insidertrades.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 24, 2025 | Crypto 101 Media (Ad)Immunovant downgraded to Neutral from Buy at UBSApril 23 at 8:34 AM | markets.businessinsider.comUBS Downgrades Immunovant (IMVT)April 23 at 8:34 AM | msn.comImmunovant appoints Eric Venker as CEO, Girao as CFOApril 22 at 1:24 AM | markets.businessinsider.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 9, 2025 | finance.yahoo.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 8, 2025 | msn.comSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $24.77 at the beginning of 2025. Since then, IMVT shares have decreased by 41.7% and is now trading at $14.45. View the best growth stocks for 2025 here. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings data on Monday, February, 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.08. Who are Immunovant's major shareholders? Immunovant's top institutional investors include Rhumbline Advisers (0.05%), GAMMA Investing LLC and FNY Investment Advisers LLC. Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, Frank Torti, William L Macias, Mark S Levine, Jay S Stout, Michael Geffner and Andrew J Fromkin. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings2/10/2025Today4/24/2025Next Earnings (Estimated)6/04/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMVT CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$38.33 High Stock Price Target$53.00 Low Stock Price Target$17.00 Potential Upside/Downside+165.3%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-259,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.94% Return on Assets-69.82% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book6.95Miscellaneous Outstanding Shares169,861,000Free Float159,839,000Market Cap$2.45 billion OptionableOptionable Beta0.81 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:IMVT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.